View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Ola Trovatn
  • Ola Trovatn

Aker Biomarine (Buy, TP: NOK65.00) - Mostly mitigating tariffs

Adj. EBITDA was USD9.0m, broadly in line with our estimate and consensus. Human Health Ingredients (HHI) beat expectations on higher volumes sold and a higher gross margin, and Emerging Businesses (EB) reported lower losses than expected from significantly reduced marketing spending. Encouragingly, management noted a limited impact of tariffs on HHI financials, where c20% of krill oil sales are from the US to China. We have only made minor adjustments to our estimates following the results, and ...

Ola Trovatn
  • Ola Trovatn

Aker Biomarine (Buy, TP: NOK65.00) - Below consensus for Q1e

We expect Q1 adj. EBITDA of USD9.4m, USD4.3m (-31%) below consensus of USD13.6m. With sales of USD51m (10% below consensus of USD57m), our estimates correspond to an adj. EBITDA margin of 18.2% versus consensus of 23.9%. The results are due at 07:00 CET on 30 April. As the strategy of maximising value through transactions for its remaining assets is the main potential share price catalyst in our view, the quarterly reported numbers would be of less relevance. We reiterate our BUY, but ha...

Ola Trovatn
  • Ola Trovatn

Aker Biomarine (Buy, TP: NOK75.00) - Delivery needed in 2025

Q4 adj. EBITDA of USD7.4m was above our USD2.1m estimate and broadly in line with consensus, albeit driven by positive adjustments. Reported EBITDA was USD3.4m, versus our USD2.1m estimate and consensus of USD6.6m. Management’s outlook comments were in line with our estimates for 2025, and we have made only minor positive EPS revisions in light of the report. As we expect a 53% increase in adj. EBITDA YOY in 2025, we highlight that delivery is needed from Q1. We reiterate our BUY and have raised...

Ola Trovatn
  • Ola Trovatn

Aker Biomarine (Buy, TP: NOK72.00) - More transactions needed

We expect Q4 adj. EBITDA of USD2.1m, USD6.9m below consensus of USD9.0m. With sales of USD54m, our estimates correspond to a margin of 3.9% versus consensus of 16.9%. The results are due at 07:00 CET on 12 February. As the strategy of maximising value through transactions for its remaining assets is the main potential share price catalyst in our view, the quarterly reported numbers are of less relevance. However, more transactions are likely needed to crystallise underlying value. We reiterate o...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch